April 11, 2018 PR-M04-18-NI-36
CONCORD, Mass., April 6, 2018 /PRNewswire/ -- Alopexx Pharmaceuticals today announced publication of additional data confirming the potential protective immunity offered by its lead monoclonal antibody, F598. The results have been published in the April 6, 2018 issue of the Journal of Biological Chemistry with the antibody structure featured on the cover. In the paper, entitled 'Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetyl glucosamine', Gerald B. Pier, Ph.D. Professor of Medicine, Harvard Medical School, Microbiologist, Brigham and Women's Hospital and senior author Paul Ramsland, Ph.D., Vice Chancellor's Principal Research Fellow at the School of Science, Engineering and Health, RMIT University in Melbourne, Australia, delineate the structure of F598 and how it binds to poly-N-acetylglucosamine (PNAG), a polysaccharide capsule found on many pathogens causing human infections, including several multi-drug resistant microbes. F598, a novel broad spectrum monoclonal antibody, is in clinical development for the prevention and treatment of serious bacterial, fungal and protozoal infections.
"This is the first study to determine the structural basis for this human antibody's recognition of PNAG, which depicts its ability to bind to many microbial pathogens," said Dr. Pier. "Of the microbial carbohydrate-binding antibodies being investigated for clinical use, F598 is unique in its ability to target a wide range of pathogens including Gram negative and Gram positive bacteria, along with fungi and protozoan parasites.
"Our monoclonal antibody F598 was shown to mediate protective immunity against PNAG-producing bacteria such as S. pneumoniae and S. aureus, other organisms causing bacterial meningitis, and a wide range of additional infectious agents, including antibiotic-resistant organisms. With the widespread use of antibiotics leading to a rise of antibiotic-resistant organisms, it is envisioned that F598 could provide immediate protective immunity to patients at a significant risk of developing a serious infection, thereby reducing or avoiding the need for antibiotics," said Hal Landy, M.D., Chief Medical Officer at Alopexx. "We are currently evaluating the clinical activity of F598 in treating and preventing a variety of infections."
Contacts:
Christine de los Reyes
(Business Development)
cdelosreyes@alopexx.com
917-319-4915
or
Gina Nugent, Nugent Communications
(Investors and Media)
gina@nugentcommunications.com
617-460-3579
SOURCE Alopexx Pharmaceuticals
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.